These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2260923)

  • 41. DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection.
    Slon Campos JL; Poggianella M; Marchese S; Mossenta M; Rana J; Arnoldi F; Bestagno M; Burrone OR
    PLoS One; 2017; 12(7):e0181734. PubMed ID: 28742857
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Simultaneous expression of the Lassa virus N and GPC genes from a single recombinant vaccinia virus.
    Morrison HG; Goldsmith CS; Regnery HL; Auperin DD
    Virus Res; 1991 Mar; 18(2-3):231-41. PubMed ID: 2042398
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses.
    Barban V; Munoz-Jordan JL; Santiago GA; Mantel N; Girerd Y; Gulia S; Claude JB; Lang J
    Virology; 2012 Aug; 429(2):91-8. PubMed ID: 22542002
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus.
    Morrison HG; Bauer SP; Lange JV; Esposito JJ; McCormick JB; Auperin DD
    Virology; 1989 Jul; 171(1):179-88. PubMed ID: 2741340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Study on E protein epitopes and primary identification of main yellow virus].
    Xu XL; Yang JJ; Ren RW; Liu JW; Ma SB; Bai ZJ; Fang MY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 May; 30(5):489-92. PubMed ID: 19799147
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status.
    Scott RM; Eckels KH; Bancroft WH; Summers PL; McCown JM; Anderson JH; Russell PK
    J Infect Dis; 1983 Dec; 148(6):1055-60. PubMed ID: 6655288
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heterologous flavivirus infection-enhancing antibodies in sera of Nigerians.
    Fagbami A; Halstead SB; Marchette N; Larsen K
    Am J Trop Med Hyg; 1988 Jan; 38(1):205-7. PubMed ID: 2829637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors.
    Khanam S; Khanna N; Swaminathan S
    Vaccine; 2006 Oct; 24(42-43):6513-25. PubMed ID: 16860446
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein.
    Raviprakash K; Kochel TJ; Ewing D; Simmons M; Phillips I; Hayes CG; Porter KR
    Vaccine; 2000 May; 18(22):2426-34. PubMed ID: 10738100
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Murine immunoglobulin G subclass responses following immunization with live dengue virus or a recombinant dengue envelope protein.
    Smucny JJ; Kelly EP; Macarthy PO; King AD
    Am J Trop Med Hyg; 1995 Oct; 53(4):432-7. PubMed ID: 7485699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunization of mice with dengue structural proteins and nonstructural protein NS1 expressed by baculovirus recombinant induces resistance to dengue virus encephalitis.
    Zhang YM; Hayes EP; McCarty TC; Dubois DR; Summers PL; Eckels KH; Chanock RM; Lai CJ
    J Virol; 1988 Aug; 62(8):3027-31. PubMed ID: 2969058
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge.
    Men R; Wyatt L; Tokimatsu I; Arakaki S; Shameem G; Elkins R; Chanock R; Moss B; Lai CJ
    Vaccine; 2000 Jul; 18(27):3113-22. PubMed ID: 10856791
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein.
    Purdy DE; Chang GJ
    Virology; 2005 Mar; 333(2):239-50. PubMed ID: 15721358
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB).
    Britt WJ; Vugler L; Stephens EB
    J Virol; 1988 Sep; 62(9):3309-18. PubMed ID: 2841483
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the nucleotide and deduced amino acid sequences of the structural protein genes of the yellow fever 17DD vaccine strain from Senegal with those of other yellow fever vaccine viruses.
    Jennings AD; Whitby JE; Minor PD; Barrett AD
    Vaccine; 1993; 11(6):679-81. PubMed ID: 8322493
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge.
    Putnak R; Feighny R; Burrous J; Cochran M; Hackett C; Smith G; Hoke C
    Am J Trop Med Hyg; 1991 Aug; 45(2):159-67. PubMed ID: 1877710
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses.
    Mantel N; Girerd Y; Geny C; Bernard I; Pontvianne J; Lang J; Barban V
    Vaccine; 2011 Sep; 29(38):6629-35. PubMed ID: 21745519
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Exchanging the yellow fever virus envelope proteins with Modoc virus prM and E proteins results in a chimeric virus that is neuroinvasive in SCID mice.
    Charlier N; Molenkamp R; Leyssen P; Paeshuyse J; Drosten C; Panning M; De Clercq E; Bredenbeek PJ; Neyts J
    J Virol; 2004 Jul; 78(14):7418-26. PubMed ID: 15220415
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection.
    Srivastava AK; Putnak JR; Warren RL; Hoke CH
    Vaccine; 1995 Sep; 13(13):1251-8. PubMed ID: 8578812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.